Introduction {#Sec1}
============

Rapidly rising life expectancy is forcing many of the world's societies to see neurodegenerative diseases as a wider social and economic issue. Such diseases have always been devastating for sufferers and their carers, but aging societies are facing a broader burden resulting from the lack of effective treatments. There is hope for disorders such as Alzheimer disease (AD), where now we have a good understanding of pathogenesis and novel treatments are on the horizon. However, two neurodegenerative disorders that remain in urgent need of attention, and that mainly but not exclusively affect the aging population, are amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD).

ALS is the third most common neurodegenerative cause of adult death after AD and Parkinson disease (<http://www.statistics.gov.uk/StatBase>) and the lifetime risk of dying from ALS lies between 1/400 and 1/1000 (Boillee et al. [@CR6]; Pasinelli and Brown [@CR35]), and in the UK 1 in 400 death certificates is issued for "motor neuron disease" (J. Stevens, personal communication). In ALS the upper motor neurons that run from the brain into the spinal cord and the lower motor neurons that extend from the spinal cord out to the muscles degenerate, leading inexorably to paralysis and death, typically within 3--5 years of diagnosis (Boillee et al. [@CR6]; Pasinelli and Brown [@CR35]; Schymick et al. [@CR43]; Valdmanis and Rouleau [@CR50]). Intellect usually remains intact and no effective treatments are available. Up to approximately 10% of ALS is familial (FALS), usually autosomal dominant, and mutations in the ubiquitously expressed enzyme superoxide dismutase 1 (SOD1) are causative in less than 20% of FALS (Deng et al. [@CR11]; Rosen et al. [@CR41]) and in approximately 1% of sporadic ALS (SALS) (Pasinelli and Brown [@CR35]). Other rare ALS mutant genes are known, usually associated with variants of ALS rather than the classic typical midlife onset disease (Boillee et al. [@CR6]; Pasinelli and Brown [@CR35]; Schymick et al. [@CR43]; Valdmanis and Rouleau [@CR50]).

FTLD is the most common cause of presenile (below 65 years of age) dementia after AD (Forman et al. [@CR13]; Harvey et al. [@CR19]; Ratnavalli et al. [@CR38]). Affected individuals have a range of characteristic traits that reflect degeneration in the frontal and temporal lobes of the brain---the areas that control behavior, emotions, and language. Early symptoms typically manifest as language difficulties and inappropriate behavior (Neary et al. [@CR31]). Up to 40% of FTLD is thought to be familial with genetically heterogeneous causes. Causative mutations have been identified in several genes, including those encoding tau (Hutton et al. [@CR22]; Poorkaj et al. [@CR37]; Spillantini et al. [@CR46]), charged multivesicular body protein 2B (*CHMP2B*) (Skibinski et al. [@CR44]), and progranulin (*GRN*) (Baker et al. [@CR5]; Cruts et al. [@CR10]), and others remain to be found. Mutations have also been identified in the valosin-containing protein (*VCP*) gene in inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia, in which frontotemporal dementia can be, but is not always, a feature (Watts et al. [@CR52]).

At first glance ALS and FTLD appear to be different disorders; however, clinicians have noted for some time that there are overlaps. FTLD symptoms are reported in up to 20% of ALS cases (Valdmanis and Rouleau [@CR50]; Van Deerlin et al. [@CR51]) and there are other intriguing connections such as families that segregate both disorders (Morita et al. [@CR29]; Valdmanis et al. [@CR49]) and imaging studies which show frontal deficits in ALS patients (Kato et al. [@CR25]). A recent study has shown that progranulin is a modifier of ALS disease progression (Sleegers et al. [@CR45]), although this was not replicated in another study (Pickering-Brown et al. [@CR36]).

Importantly, in common with several other neurodegenerative disorders, ALS and FTLD both present with aggregates of misfolded proteins in the cytoplasm and/or nucleus of neurons. Ubiquitinated inclusion bodies have been reported in the cytoplasm of neurons of both SALS and FALS cases and in mutant *SOD1* transgenic mice that model FALS (for further discussion see Boillee et al. [@CR6]; Pasinelli and Brown [@CR35]). FTLD is subdivided into two classes based on the content of the inclusion bodies: (1) those with tau-positive and ubiquitin-negative inclusions (tauopathies) and (2) more common forms with ubiquitinated but tau-negative inclusions known as FTLD-U, including *PGRN*, *VCP*, and *CHMP2B* mutations (reviewed in Mackenzie and Rademakers [@CR28]). ALS and FTLD-U cases both present with cytoplasmic ubiquitin-positive, tau-negative inclusions indicating that there are at least some common pathway(s) involved in the pathogenesis of these diseases.

**TDP-43---the new kid on the block** {#Sec2}
=====================================

Research into ALS and FTLD-U was radically redirected by the appearance of a new player in 2006. In that year, Neumann, Trojanowski, Lee, and colleagues provided a molecular connection between these disorders by finding that a protein called the TAR DNA-binding protein (TDP-43) is the major protein in the inclusion bodies in both disorders (Neumann et al. [@CR32]), which was quickly confirmed (Arai et al. [@CR2]). Some authors now refer to the TDP-43 inclusion positive types of ALS and FTLD-U as different forms of the same neurodegenerative disorder: TDP-43 proteinopathy (Cairns et al. [@CR9]; Kwong et al. [@CR26]; Winton et al. [@CR53]). TDP-43 positive inclusions have now also been reported in cases of Alzheimer disease, Pick disease, dementia with Lewy bodies, and other neurodegenerative disorders, and are seen in glia as well as neurons (Amador-Ortiz et al. [@CR1]; Freeman et al. [@CR14]; Geser et al. [@CR15]; Hasegawa et al. [@CR20]; Higashi et al. [@CR21]; Nakashima-Yasuda et al. [@CR30]; Neumann et al. [@CR33]).

TDP-43 is a 414-residue, 43-kDa protein, first identified as a binding partner of the TAR DNA element of the human immunodeficiency virus (Ou et al. [@CR34]). Currently we know that TDP-43 is a ubiquitously expressed, highly conserved nuclear protein encoded by a 6-exon gene (*TARDBP* on human chromosome 1p36.2). The protein consists of two RNA recognition motifs and a glycine-rich domain (Fig. [1](#Fig1){ref-type="fig"}). It is found in nuclear bodies, colocalized with SMN and gemin proteins, and may function as a transcriptional repressor and as an activator of exon skipping, or in other roles such as in miRNA biogenesis, apoptosis, and cell division (Ayala et al. [@CR4], [@CR3]; Buratti et al. [@CR8]; Johnson et al. [@CR23]; Winton et al. [@CR53]). In the TDP-43 proteinopathies TDP-43 is depleted from the nucleus and is sequestered as hyperphosphorylated insoluble aggregates in the nucleus, perikarya, and dystrophic neurites (Neumann et al. [@CR32]). Perturbation of the trafficking of TDP-43 between the nucleus and cytoplasm is thought to lead to the formation of these aggregates; brain samples from both ALS and FTLD-U are enriched for a smaller (∼25 kDa) phosphorylated C-terminal fragment and high-molecular-weight ubiquitinated species (Neumann et al. [@CR32]; Winton et al. [@CR53]). Inhibition of autophagy can also lead to the relocalization of TDP-43 from the nucleus to the cytoplasm in vitro (Filimonenko et al. [@CR12]). Fig. 1TDP-43 mutations in ALS. TDP-43 is encoded by a 6-exon gene, of which exons 2-6 are protein coding (top). The TDP-43 protein contains four known functional domains: a nuclear localization sequence, two central RNA Recognition Motifs (RRM1 and RRM2), and a C-terminal glycine-rich domain, predicted to mediate protein-protein interactions. All disease mutations so far are found in the glycine-rich domain (encoded by exon 6), with the exception of one mutation in RRM1 (encoded by exon 4). A mutation in the nuclear localization domain has been reported in two unaffected controls (data compiled from Gitcho et al. [@CR17]; Kabashi et al. [@CR24]; Sreedharan et al. [@CR47]; Van Deerlin et al. [@CR51]; Yokoseki et al. [@CR54])

Intriguingly, while TDP-43 is deposited in sporadic and familial FTLD-U and in sporadic and non-SOD1 familial ALS (Kwong et al. [@CR26]; Neumann et al. [@CR32]), it is not found in inclusions in SOD1 FALS (Mackenzie et al. [@CR27]; Tan et al. [@CR48]) or in the *SOD1*^*G93A*^, *SOD1*^*G37R*^, and *SOD1*^*G85R*^ transgenic mouse models of FALS (Robertson et al. [@CR39]).

TDP-43 is a criminal, not just a bystander {#Sec3}
==========================================

The identification of TDP-43 in ALS and FTLD-U inclusion bodies immediately led to surveys of patient cohorts to find either association with or mutations in the gene. All returned with negative results (e.g., see Gijselinck et al. [@CR16]; Rollinson et al. [@CR40]; Schumacher et al. [@CR42]), leading to the reasonable conclusion that TDP-43 deposition may simply be a *consequence* of disease and therefore possibly of less interest in providing novel insight into the *cause* of these diseases. However, in 2008 all this has changed with the publication of five articles, all of which report rare TDP-43 mutations in sporadic and familial ALS in patients of different ethnicities (mainly but not exclusively Caucasian) (Gitcho et al. [@CR17]; Kabashi et al. [@CR24]; Sreedharan et al. [@CR47]; Van Deerlin et al. [@CR51]; Yokoseki et al. [@CR54]). In summary (Fig. [1](#Fig1){ref-type="fig"}, Table [1](#Tab1){ref-type="table"}), all the mutations lie in exon 6 except for one in exon 4. The FALS cases are autosomal dominant with some variability in presentation, bulbar and limb onset cases, some with more or less lower motor neuron loss and different ages of onset and rates of progression, but all fairly classic FALS. No dementia is found, although Kabashi et al. ([@CR24]) report apathy, major anxiety, and agitation in two individuals. For cases in which postmortems have been carried out, TDP-43 deposition has been found in the brains of affected individuals (Van Deerlin et al. [@CR51]; Yokoseki et al. [@CR54]). Table 1Novel mutations in the gene encoding TDP-43SALS = sporadic amyotrophic lateral sclerosis; FALS = familial amyotrophic lateral sclerosis; MND = motor neuron disease; *GRN* = progranulin; *SOD1* = Cu/Zn superoxide dismutase 1; *MAPT* = microtubule-associated protein tau; *CHMP2B =* chromatin modifying protein 2B; *VAPB* = synaptobrevin-associated membrane protein B; *ANG* = angiogenin; *DCTN1* = dynactin.Each mutation is absent in the control group. Fourteen missense mutations lie in the glycine-rich domain of the protein encoded by exon 6 of *TARDBP* and one mutation lies in the first RNA binding domain (D169G)^1^mean age of onset, ^2^FTLD and related disorders, see text for details, ^3^all exons sequenced, ^4^only the specific variants were analyzed, full sequencing was not performed, ^5^only exon 6 sequenced, ^6^method of detection not described, ^f^mutation found in familial ALS, or ^s^individuals with no known family history of ALS

The mutations are already starting to give some insight into pathogenesis (Gitcho et al. [@CR17]; Kabashi et al. [@CR24]; Sreedharan et al. [@CR47]; Van Deerlin et al. [@CR51]; Yokoseki et al. [@CR54]). Disruption of protein interactions is one possible disease mechanism. Most mutations lie in the C-terminal, a glycine-rich region that may mediate interactions with proteins, including heterogeneous ribonucleoproteins. Also, some of the mutations found in this region could increase phosphorylation by substituting threonine or serine residues or through the creation of a new protein kinase A site (Sreedharan et al. [@CR47]). This may result in disruption of protein interactions and/or disruption of transport through the nuclear pore complex. In transfected cell lines and patient lymphocytes some variants also show a clearly increased propensity to aggregate and to produce a lower-molecular--weight, detergent-insoluble protein product (Kabashi et al. [@CR24]; Sreedharan et al. [@CR47]; Yokoseki et al. [@CR54]). One mutation, D169G, lies in the first RNA-binding motif and may affect RNA binding (Kabashi et al. [@CR24]). When mutant TDP-43 is electroporated into the neural tube of developing chick embryos, two different mutations showed a reduction in rate of maturation of the neural tube with an increase in apoptotic nuclei, suggesting a toxic gain of function or dominant negative effect (Sreedharan et al. [@CR47]).

It is noteworthy that just one mutation lies in exon 4, within the first RNA recognition motif (RRM 1), whereas the other 13 mutations identified so far occur in exon 6, in the putative protein interaction domain. This raises the question of whether the exon 4 mutation (D169G) is a genuine pathogenic mutation and, if so, if it leads to disease via a different effect on TDP-43 function than the other mutations. D169 is a highly conserved amino acid (Kabashi et al. [@CR24]) and the mutation was absent in 360 ethnically matched controls from France (Kabashi et al. [@CR24]), as well as in 872 nonethnically matched controls (700 British, 172 Australian) for which all exons of TDP-43 were sequenced in the study of Sreedharan et al. ([@CR47]). The absence of the mutation in a large number of controls and the evolutionary conservation of the amino acid argue for a pathogenic role; however, absence in a larger number of ethnically matched controls and functional data or the identification of further mutations in RRM 1 will be required to fully resolve this issue. If D169G is pathogenic, then it suggests that mutations in the C-terminal domain, and the RRM1 domain, which has been shown to be essential for the RNA-binding ability of TDP-43 (Buratti and Baralle. [@CR7]), affect the function of TDP-43 in a similar way, such as a general loss of function, or that there are different ways to disrupt TDP-43 function and still lead to disease.

Rare single-gene defects, protein aggregates, and neurodegeneration---sounds familiar {#Sec4}
=====================================================================================

The identification of the major protein in neurodegenerative disease inclusion bodies, followed by finding rare mutations in the gene encoding this protein, is a powerful route to understanding pathogenesis and is turning into a surprisingly common approach in neurodegenerative diseases. It is exemplified by the classic example of finding mutations in the amyloid precursor protein (*APP*) gene that encodes the Abeta peptide deposited in the plaques of Alzheimer disease; it revolutionized our understanding of AD (Hardy and Selkoe [@CR18]). Similar rare dominant single-gene mutations have also been found in the proteins that aggregate in Parkinson disease, prion diseases, and tauopathies, for example, also giving us great insight into the pathogenesis of these disorders. The articles that reported on TDP-43 mutations in ALS have shifted the focus of attention on this protein from being deposited as a by-product of disease processes to actually being a causative agent that triggers the processes resulting in neuronal death. From this point investigations will proceed using transgenic and knockout mice and a variety of different cellular systems to understand the link between mutation and disease.

Many questions need to be addressed, such as does TDP-43 take on a toxic gain of function when mutated in ALS, as happens with *SOD1* mutations in ALS? Will TDP-43 mutations be found in cases of FTLD-U, and if not, why not? How important is timing? Does having a germline TDP-43 mutation give rise to ALS which might develop into FTLD-U if individuals lived long enough? Another question is: What separates TDP-43 ALS from SOD1 ALS? These two diseases are very similar at a clinical level, but clearly different pathways are affected for at least some of the pathogenesis. We assume that there are many parallel cellular pathways, which, if disrupted can lead to the same outcome. TDP-43 ALS and SOD1 ALS may allow the investigation of this phenomenon.

The new mutations found in TDP-43 are a breakthrough for ALS and FTLD-U research and we are looking forward to seeing what new discoveries they herald to help us treat and ultimately cure these terrible neurodegenerative diseases.
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